BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
Sun Yat-sen University · Sun Yat-sen University Cancer Center · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
115
total citations
- FWCI
- 29.04
- Percentile
- 100%
- References
- 27
Citations per year
Authors
25- YMYuxiang Ma
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- YHYan Huang
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- YZYuanyuan Zhao
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- SZShen Zhao
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- JXJinhui Xue
Sun Yat-sen University, Sun Yat-sen University Cancer Center
Topics & keywords
Topics
Keywords
- Conjugate
- Medicine
- Drug
- Antibody-drug conjugate
- Open label
- Phases of clinical research
- Antibody
- Bispecific antibody
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.